Effective senior scientist with 19 years of laboratory experience in biotechnology with emphasis on molecular biology assay development, co-inventor on 4 telomerase patents, and influential track record investigating telomere biology and age-related disease. Responsible for spearheading a successfully redesigned drug discovery operation leading to the discovery of telomerase activators TAM-818 and IsaGenesis® while boosting company revenue over $1.5 million. Goal-oriented leader who encourages employees to deliver results in a professional, organized, productive manner. Seeking senior scientist position in molecular biology, or related field, to execute exciting research with fresh challenges.
Lead science operations by driving development of novel therapies for aging-related disease in humans using small-molecule drug discovery, nutraceutical development, and gene therapy while mobilizing efforts to incorporate new technologies (RNAseq, CRISPR, NanoString) into telomerase research. Actively collaborating with medical professionals in drafting clinical protocols for AAV hTERT gene therapy to treat Alzheimer's, Cardiomyopathy, Critical Limb Ischemia, and Idiopathic Pulmonary Fibrosis while building business partnerships with Libella Gene Therapeutics and DefyTime.
Developed multiplexed cell-based qRT-PCR high-throughput drug screening assay to detect hTERT mRNA and reference gene expression in normal human somatic cells down to 0.005 mRNA copies/cell, utilizing magnetic oligo(dT) beads in 96-well format RNA isolations, and CellTiter-Glo Luminescent Cell Viability assays of lysate aliquots in tandem. This robust assay served as driving force for redesigning drug discovery operations to screen 10,000+ compounds per week with established quality control practices.
Executed 3 research projects over 3 years in molecular biology, protein chemistry, and assay development to discover transcription factor(s) responsible for repressing hTERT gene expression in normal human somatic cells.
Recognized by leadership as best employee in molecular biology with unparalleled efficiency, completing complex plasmid construction projects while generating 3,000+ plasmids to characterize the hTERT minimal promoter months ahead of schedule.
Andrews, William H.; Brown, Lancer K.; Mohommadpour, Hamid; Briggs, Laura A. “Enhancing health in mammals using telomerase reverse transcriptase gene therapy.” US Patent Number: 10,485,852. Date: November 26, 2019.
Andrews, William H.; Brown, Lancer K.; Mohommadpour, Hamid; Briggs, Laura A. “Enhancing health in mammals using telomerase reverse transcriptase gene therapy.” US Patent Number: 9,453,209. Date: September 27, 2016.
Fahy, Gregory M.; Brown, Lancer. “Nutritional activation of telomerase in-vitro with increased safety.” US Patent Number: 8,815,899. Filed on August 26, 2014.
Andrews, William H.; Briggs, Laura A; Brown, Lancer K.; Foster, Christopher A.; Piatyszek, Mieczyslaw A. "Assays for TERT promoter modulatory agents using a telomerase structural RNA component." US Patent Number: 7,226,744. Date: June 5, 2007.
Coussens, M., Davy, P., Brown, L., Foster, C., Andrews, W.H., Nagata, M., Allsopp, R. (2010) RNAi screen for telomerase reverse transcriptase transcriptional regulators identifies HIF1a as critical for telomerase function in murine embryonic stem cells. PNAS 107(31): 13842-7.
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Companies Worked For:
Job Titles Held: